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t(8;21) is a frequent chromosomal translocation in acute myeloid
leukemia (AML) and is also reported in lymphoid and bipheno-
typic acute leukemia.1,2 t(8;21) fuses the RUNX1 gene (AML1) on
chromosome 21 to the ETO gene (RUNX1T1) on chromosome 8,
encoding the RUNX1/ETO chimeric transcription factor that
represses expression of RUNX1 target genes, promoting self-
renewal and blocking myeloid differentiation.3–6 t(8;21) is
insufficient for leukemogenesis and additional co-operating
mutations are required for transformation,7 including point
mutations that activate and/or over express c-KIT.8 The mechan-
isms driving the acquisition of co-operating mutations remain
unclear, although there is evidence that initiating lesions such as
RUNX1/ETO may promote mutagenesis.9,10 For example, ectopic
expression of RUNX1/ETO downregulates several DNA-repair
proteins (BRCA2, OGG1 and ATM) and increases the level of
phosphorylated TP53 and γH2AX, indicating elevated DNA
damage and a possible pro-mutagenic phenotype.10,11
To test whether expression of RUNX1/ETO is sufficient to
increase genomic instability and mutagenesis, we expressed
RUNX1/ETO in the non-transformed TK6 lymphoblastoid cell
line and measured the acquisition of mutations at the PIGA
reporter gene. Cells were transduced with lentivirus carrying
either enhanced green fluorescent protein (EGFP) and the
RUNX1/ETO fusion or EGFP alone (vector control) (Supplementary
Figure 1A; Supplementary Methods) and clones expressing both
RUNX1/ETO mRNA and protein were generated (Supplementary
Figures 1B and C). For the purposes of measuring RUNX1/ETO-
induced mutagenesis, we analysed independent cell clones
expressing at least 40% of the fusion transcript found in the
Kasumi-1 and SKNO-1 t(8;21)-positive cell lines (Supplementary
Figure 1B). Monitoring of RUNX1/ETO-positive clones revealed
that expression of the fusion was stable over long culture
periods (412 weeks). Independent vector control clones that
expressed equivalent levels of EGFP to RUNX1/ETO-positive cells
were used as fusion-protein negative controls (Supplementary
Figure 1D).
PIGA encodes a protein essential for production of the
glycosylphosphatidylinositol anchor, mediating anchoring of
proteins including CD55 and CD59 to the cell membrane.12
Somatic mutations of PIGA are growth neutral and can be
determined using flow cytometry analysis measuring CD55 and
CD59 expression (Supplementary Figure 2; Supplementary
Methods). Using this reporter gene system we determined the
mutation frequency (Mf) in several independent RUNX1/ETO-
expressing and vector control clones after continuous culture for
8–10 weeks after initial cloning. All clones had a majority
population that was positive for CD55 and CD59, confirming that
the founding cell was PIGA wild-type (WT). The mean PIGA Mf in
RUNX1/ETO clones (7.50 × 10− 4) was five times higher than in
vector control clones (1.45 × 10− 4) (Figure 1a, Supplementary
Figure 3A) (P= 0.032), with the exception of a single clone that had
low expression of the fusion transcript (equivalent to 40% of that
in Kasumi-1) (Supplementary Figures 1B and 3A).
The frequency of cells with a mutation (Mf) at a specific gene is
determined by the mutation rate per cell division for that gene (μ)
and the number of cell divisions (d). Expression of the RUNX1/ETO
fusion had a modest but nonsignificant negative effect on cell
proliferation (Figure 1b, Supplementary Figure 3B, P= 0.812),
confirming that the increased Mf in RUNX1/ETO fusion-positive
cells was not due to elevated proliferation.
Despite being derived from single cells, EGFP expression in
RUNX1/ETO clones was normally distributed in all cell populations
(Figure 1c, Supplementary Figure 4), indicating a natural drift in
EGFP post cloning. Our data suggest that RUNX1/ETO confers a
mutator phenotype in a protein-level-dependent fashion. By using
EGFP as a surrogate for RUNX1/ETO we predicted that PIGA-mutant
cells would have higher EGFP expression compared with non-
mutant cells from the same population. Consistent with this
hypothesis, the EGFP geometric mean of fluorescence (GMoF) of
PIGA mutant cells derived from RUNX1/ETO cell clones was
significantly higher than in non-mutants derived from the same
starting population (Figures 1c and d, Supplementary Figure 4,
Supplementary Table 1). The only RUNX1/ETO clone that did not
show a difference between EGFP GMoF for PIGA WT and mutant
cells was that with the lowest RUNX1/ETO expression
(clone RE4), which also had no increase in spontaneous PIGA Mf
(Supplementary Figure 3A). For vector control clones, the EGFP
GMoF was not significantly different between PIGA mutant and
WT cells (Figure 1d, Supplementary Figure 4, Supplementary
Table 1). These data demonstrate that expression of the RUNX1/
ETO fusion oncoprotein confers a mutator phenotype when the
transcript is at levels equivalent to at least 60% of that in t(8;21)-
positive cell lines.
We next investigated whether RUNX1/ETO transduced cells
were particularly sensitive to mutagenesis following exposure to
genotoxic anticancer therapies. Fusion protein-positive and vector
control clones were exposed to sub-cytotoxic doses of either
doxorubicin (100 nM for 4 h) or ionising radiation (3 Gy), and Mf
was measured 2 weeks after treatment. The frequency of
mutations attributable to doxorubicin or radiation (treatment-
induced Mf) was calculated by subtracting the Mf in mock-treated
cells from the Mf in doxorubicin- or radiation-treated cells. The
mean treatment-induced PIGA Mf was strongly inceased in
RUNX1/ETO cell clones compared with vector control clones
following either doxorubicin (mean Mf=6.54×10−4 vs 0.208×10−4,
P= 0.09) or radiation treatment (mean Mf= 5.92 × 10− 4 vs
0.209 × 10− 4, P= 0.008) (Figure 2a, Supplementary Figure 5).
As an additional independent measure for treatment-induced Mf
we assayed RUNX1/ETO and vector control clones at a second
reporter gene, thymidine kinase (TK). The mean treatment-
induced TK Mf was also significantly higher in RUNX1/ETO cell
clones compared with vector control clones following either
doxorubicin (mean Mf= 3.53 × 10− 6 vs 0.432 × 10− 6, P= 0.014) or
radiation treatment (mean Mf= 6.43 × 10− 6 vs − 0.145 × 10− 6,
P= 0.002) (Figure 2a, Supplementary Figure 5). The only RUNX1/
ETO clone that did not show increased sensitivity to doxorubicin
or radiation-induced mutation was clone RE4 with low RUNX1/ETO
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expression (Supplementary Figure 5). For both PIGA and TK, the Mf
in vector control clones following doxorubicin or radiation
treatment was not significantly different from mock-treated cells
(Figure 2a, Supplementary Figure 5), suggesting that, unlike
RUNX1/ETO-expressing cells, vector control cells were proficient at
repairing treatment-induced DNA damage.
We next investigated whether EGFP expression differed in
treatment-induced PIGA mutant cells compared with non-mutant
cells derived from the same RUNX1/ETO clonal population. The
EGFP GMoF of PIGA mutant cells was significantly higher than in
non-mutant cells following treatment with doxorubicin (P= 0.03)
or ionising radiation (P= 0.02) (Figures 2b and c, Supplementary
Figure 6). In contrast, the EGFP GMoF was not significantly
different between PIGA mutant and WT cells derived from vector
control populations following treatment (Figures 2b and c).
These data demonstrate that high levels of RUNX1/ETO sensitise
cells to acquisition of mutations following treatment with DNA
damage-inducing agents, suggesting that fusion-protein-expressing
cells may be compromised in DNA repair. This result is consistent
with previously published reports implicating compromised OGG1
DNA glycosylase activity in t(8;21) AML.11,13 OGG1 functions in base
excision repair and initiates repair of oxidised lesions, including
8-hydroxy-2′-deoxyguanosine. We therefore investigated OGG1
expression in 18 independent RUNX1/ETO cell clones and observed
that transcript levels were inversely proportional to the expression of
the fusion gene (Supplementary Figure 7A). Likewise, OGG1 protein
levels were consistently lower in RUNX1/ETO-positive clones
compared with vector control clones (Supplementary Figure 7B).
We next performed siRNA-mediated depletion of RUNX1/ETO in
Kasumi-1, as previously described.5 Two serial electroporations with
either RUNX1/ETO or control scrambled siRNA were carried out and
OGG1 transcript and protein levels were assessed 72 h after each
electroporation. RUNX1/ETO depletion increased OGG1 transcript
levels by fourfold and sixfold on days 3 and 6, respectively
(Supplementary Figure 7C) with a concomitant increase in OGG1
protein (Supplementary Figures 7C and D). To confirm OGG1 as a
RUNX1/ETO target gene we performed ChIP and RNA sequencing
after siRNA-mediated RUNX1/ETO depletion. A RUNX1/ETO CHiPseq
peak was observed at the OGG1 promoter in control-transfected
Kasumi-1 cells, which was lost following siRNA-mediated fusion
protein depletion (Supplementary Figure 7E) and was co-localised
within a DNaseI hypersensitivity site, as previously reported.6 We
also confirmed the increase in OGG1 expression after RUNX1/ETO
depletion by RNAseq (Supplementary Figure 7E). Taken together,
these data confirm that the RUNX1/ETO fusion protein binds the
OGG1 promoter and negatively regulates transcription, suggesting a
plausible mechanism by which this common fusion oncoprotein
drives mutagenesis. In order to investigate this further, we
interrogated whole-genome and exome sequencing data from
The Cancer Genome Atlas Project.14 Data were available from 193
AML cases, which included information on 21 386 somatic base
substitution mutations, including G4T transversions, the pre-
dominant mutation that arises following translesion synthesis of 8-
hydroxy-2′-deoxyguanosine and which accumulates following
knockdown of OGG1 in experimental systems.15 When stratified
by cytogenetic subgroup, 16.13% of all mutations in t(8;21) AML
were G4T transversions (16.13%, n= 7 cases, Supplementary
Table 2), which was higher than any other cytogenetic subgroup
and all other AML cases combined (12.14%, n= 186 cases),
although this did not reach statistical significance (P= 0.31, Yates
chi-square). These data are consistent with loss of OGG1
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Figure 1. Expression of RUNX1/ETO increases spontaneous Mf. (a) RUNX1/ETO clones (black bar) and vector control clones (white bar) were
assayed for Mf at the PIGA gene. RUNX1/ETO and vector control clones were cultured post cloning for 8–10 weeks before assessment of PIGA Mf.
Mf was calculated by quantifying the number of PIGA-negative cells, which had passed all gating steps described in Supplementary Figure 2
and dividing this by the total number of cells that had passed all gating steps described in Supplementary Figure 2. Mf values are the mean of
five RUNX1/ETO clones and four vector control clones. RUNX1/ETO clones showed a significant increase (P= 0.032) in PIGA Mf compared with
vector control clones. (b) Growth curves of RUNX1/ETO (solid line) and vector control cells (dashed line). Cells were seeded at 2 × 104/ml and
cell proliferation in six RUNX1/ETO clones and five vector control clones was measured every 24 h for 4 days. Mean cells/ml value of all clones
is displayed and error bars represent the s.d. No significant difference was observed between the proliferation of RUNX1/ETO clones and
vector control clones (P= 0.812; ANOVA). (c) Example flow cytogram plots showing a higher EGFP level in PIGAmutant cells (bottom left panel)
compared with WT PIGA cells (top left panel) from a single RUNX1/ETO clone. In contrast, differential EGFP expression between PIGA
mutant and WT cells was not observed in vector control cells from a single clone (right panels) (further examples are shown in Supplementary
Figure 4). Numbers represent EGFP geometric mean of fluorescence (GMoF). (d) EGFP levels in PIGA mutant and WT cells. EGFP levels
(a surrogate for RUNX1/ETO) in PIGA mutant and WT cells were measured in RUNX1/ETO clones (black bars) and vector control clones
(white bars) and represented as fold change of EGFP fluorescence between PIGA WT and mutant cells. Histogram shows the mean from five
RUNX1/ETO clones and four vector control clones. Error bars represent the standard deviation. RUNX1/ETO PIGA mutants had significantly
higher EGFP fluorescence than PIGA WT RUNX1/ETO cells from the same population, whereas no significant difference was observed between
vector control PIGA mutant and WT cells (P= 0.045; one tailed unpaired Student’s t-test using fold change in fluorescence between PIGA WT
and mutant cells and comparing RUNX1/ETO clones and vector control clones).
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contributing to the mutator phenotype in RUNX1/ETO cells by
predisposing to G:C4T:A transversions.
By using mutation assays using two independent assays, we
have shown that RUNX1/ETO predisposes to the acquisition of
mutations, both spontaneously and particularly after treatment
with genotoxic agents. We also present evidence that the strength
of the mutator phenotype is related to the expression level of the
fusion protein. As with all types of AML, relapse is a major cause of
mortality in t(8;21) AML. If remission–induction chemotherapy fails
to eliminate all the RUNX1/ETO-positive cells, our data suggest
that surviving cells are predisposed to mutations that could drive
relapse. One consideration for chemotherapy should therefore be
to limit mutation of surviving leukemic/preleukemic cells. As such,
we hypothesise that targeting the mutator phenotype associated
with expression of the RUNX1/ETO fusion gene could impede the
acquisition of co-operating mutations required for disease relapse.
Our data demonstrate the need to develop novel therapeutic
strategies that avoid increasing the mutation burden of AML cells.
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